Find public news by keyword, exact ticker, category and date.
Open a ticker page for its news coverage. The news search below stays a text search.
2 results loaded, newest first. End of these results. The latest changes are still being indexed. Try again shortly for updated results.
Envudeucitinib did not meet primary or secondary endpoints in the overall SLE population, but showed robust efficacy and a favorable safety profile in the IFNGS-high subgroup. Future development will focus there, with regulatory engagement planned by year-end.
Alms’ phase IIb LUMUS trial of envudeucitinib in SLE did not meet primary or secondary endpoints overall. The IFNGS-high subgroup showed robust efficacy for phase III focus; safety was favorable, with regulatory engagement planned by year-end.